Omics-based biomarkers: current status and potential use in the clinic
Omics-based biomarkers: current status and potential use in the clinic
复制标题
DOI：
10.1016/j.bmhimx.2017.03.003
复制
发表时间：
2017-06-01
期刊：
影响因子：
--
通讯作者：
Aguirre-Hernández, Jesús
中科院分区：
文献类型：
--
作者：
Quezada, Héctor;Guzmán-Ortiz, Ana Laura;Aguirre-Hernández, Jesús
近年来，高通量组学技术的使用导致了许多候选生物标志物的快速发现。然而，他们中很少有人能过渡到诊所。在这篇综述中，组学技术的承诺，以促进生物标志物的发展过程中进行了描述。概述了目前在这一领域的状态与肿瘤学领域的基因组学，蛋白质组学，转录组学，代谢组学和微生物生物标志物的例子，沿着一些建议的策略，以加快他们的验证和翻译，以改善肿瘤患者的护理。肿瘤固有的复杂性与基于组学技术开发精心设计的生物标志物发现过程的要求相结合，对有效开发可用于指导治疗、解决疾病风险和预测临床结果的生物标志物提出了挑战。(C)2017年墨西哥婴儿医院Federico Gomez。出版社：Masson Doyma Mexico S. A.这是一个CC BY-NC-ND许可下的开放获取文章。
In recent years, the use of high-throughput omics technologies has led to the rapid discovery of many candidate biomarkers. However, few of them have made the transition to the clinic. In this review, the promise of omics technologies to contribute to the process of biomarker development is described. An overview of the current state in this area is presented with examples of genomics, proteomics, transcriptomics, metabolomics and microbiomics biomarkers in the field of oncology, along with some proposed strategies to accelerate their validation and translation to improve the care of patients with neoplasms. The inherent complexity underlying neoplasms combined with the requirement of developing well-designed biomarker discovery processes based on omics technologies present a challenge for the effective development of biomarkers that may be useful in guiding therapies, addressing disease risks, and predicting clinical outcomes. (C) 2017 Hospital Infantil de Mexico Federico Gomez. Published by Masson Doyma Mexico S. A. This is an open access article under the CC BY-NC-ND license.